how many people are using glp-1 Here's Americans say they now taking drugs GLP-1 Use Has More Than

Its double-wall insulation keeps beverages cold all day, and the filter straw is removable if youd prefer to swig rather than sip

Dosing Protocol Key Efficacy Data The SURMOUNT clinical trial program established tirzepatide as the most effective GLP-1 weight loss agent currently available: SURMOUNT-1 (adults without diabetes): Mean weight loss of 20.9% (10 mg), 24.0% (15 mg) at 72 weeks versus 3.1% placebo (Jastreboff et al., NEJM , 2022) SURMOUNT-2 (adults with type 2 diabetes): Mean weight loss of 12.8% (10 mg), 14.7% (15 mg) at 72 weeks (Garvey et al., Lancet , 2023) SURMOUNT-3 (after intensive lifestyle intervention lead-in): Mean total weight loss of 26.6% with tirzepatide 15 mg (Wadden et al., Nature Medicine , 2023) SURMOUNT-4 (withdrawal study): Patients who discontinued tirzepatide after 36 weeks regained approximately two-thirds of lost weight by week 88, demonstrating the chronic disease nature of obesity and the need for ongoing treatment (Aronne et al., JAMA , 2024) Why Dual Agonism Matters The GIP receptor activation in tirzepatide produces additive effects beyond GLP-1 agonism alone

Weeks 1-4: Adjustment and Early Appetite Changes In the first few weeks, many patients report reduced appetite and decreased food cravings

These participants also tended to walk faster following treatment, suggesting improved physical function

Some people feel like they have fully returned to their pre-medication state